Rijnstate Ziekenhuis Stichting — Clinical Trial Site

163 Registered trials

81 Currently recruiting

Organisation

Rijnstate Ziekenhuis Stichting

Location

Arnhem, Netherlands

Identifier

ORG-100021667

Address

Wagnerlaan 55, 6815 AD, Netherlands

Departments

-
#2915:Cardiology
#3714: Cardiology
2401: Medical oncology
3021: Neurology
3714: Cardiology
4001: Cardiology
Afd. Inwendige geneeskunde
Afdeling interne Geneeskunde
Cardiologie
Cardiology
Cardiology Department
chirurgie
Department of Haematology-Internal Medicine
Department of Medical Oncology
Department of Neurology
Department of Pulmonary Medicine
Dept. of Internal Medicine
Emergency Department
Gastroenterology
Gastroenterology & Hepatology
Gastroenterology and hepatology
Gynaecologie
Gynaecology
Hematology
Intensive Care
Intensive care unit
Internal Medicine
Internal Medicine, Vascular Medicine
Interne geneeskunde
Internist
Longgeneeskunde
Longgeneeskunde (longziekten)
Lung
Lung Diseases
MDL
Medical oncology
Medische Oncologie
N/A
NA
Nephrology
Neurologie
Neurology
NLD004:Pulmonology
Nuclear Medicine
Oncology
Oncology center
Oncology department
Orthopaedics
orthopedic surgery
Paediatric Gastroenterology
Paediatrics
Pediatrics
Pneumology
Poli Lung diseases
Psychiatry
Pulmanory Medicine Department
Pulmonary Science
Pulmonology
radiologie en nucleaire geneeskunde
Reproductive medicine and gynecology
Research Facility
Rheumatology
Rijnstate Ziekenhuis Stichting
stomach liver intestine department
Surgery
Trialbureau KCHL
urology
Vasculair geneeskunde
Vascular Centre
Vascular medicine
Ward (Internal Medicine)
Ziekenhuis Rijnstate

Clinical trials at this site (163)

Search interface

Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS) Ended

2024-513105-31-00 Multiple Sclerosis 6 2024-07-30
DUTCH-WAIST Ended

2022-501392-81-00 Obesity 6 2024-07-25
TGF‐β And PDL‐1 inhibition with Bintrafusp alfa in Esophageal Squamous Cell carcinoma combined with chemoradiation TheRapY (TAPESTRY) Ended

2023-503312-32-00 Esophageal squamous cell carcinoma 4 2024-06-24
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i… Ended

2023-506906-38-00 Follicular Lymphoma 5 2024-05-23
An international prospective open-label, multi-center, randomized, non-comparative phase II study of lutetium [177Lu] vipivotide tetraxetan … Ended

2022-503040-41-00 PSMA PET scan positive Castration-Resistant Prostate Ca 4 2024-02-09
A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended

2022-502442-27-00 Obesity 5 2024-01-08
Aspirin to prevent cardiovascular events in patients with pneumonia or influenza Ended

2023-504553-12-01 Influenza 6 2023-12-27
Phase 3 study of belzutifan plus pembrolizumab as adjuvant treatment in renal cell carcinoma (RCC) Ended

2023-505023-31-00 Renal cell carcinoma 5 2023-11-17
Safe, effective and cost-effective oxygen saturation targets for children and adolescents with respiratory distress: a randomized controlled… Ended

2023-504817-56-00 Bronchiolitis 6 2023-09-05
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
HOVON 164 HL: Tislelizumab plus Gemcitabine and Cisplatin for Relapsed or Refractory Hodgkin Lymphoma followed by Tislelizumab Consolidation… Ended

2022-502225-17-00 Hodgkin lymphoma 4 2023-07-14
A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Ended

2022-501999-26-00 Severe Hypertriglyceridemia (SHTG) 5 2023-07-12
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS Ended

2022-502664-21-00 multiple sclerosis 6 2023-05-01
A Phase 3, 52-Week, Randomized, Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory or Une… Ended

2024-513460-26-00 Refractory Chronic Cough, Including Unexplained Chronic 5 2023-03-29
Does progesterone luteal phase support increase live birth rates in couples undergoing intra-uterine insemination with Mild Ovarian HyperSti… Ended

2022-501534-33-00 Unexplained Subfertility, infertility 6 2023-03-06
REDUCE PMR: Rituximab Effect on Decreasing glUcoCorticoid Exposition in relapsing PolyMyalgia Rheumatica Ended

2024-513545-37-00 Polymyalgia rheumatica 6 2023-02-09
A Study of Tirzepatide (LY3298176) on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT- MMO) Ended

2022-501744-15-00 Obesity, Overweight 5 2023-01-23
Impact of peri-operative tEstosterone levels oN Functional and oncological Outcomes following RadiCal prostatEctomy Ended

2024-511340-29-02 Late-onset hypogonadism 5 2022-12-14
A research study to see how well CagriSema helps people with excess body weight lose weight Ended

2023-506929-11-00 Overweight and obesity 5 2022-10-17
Phase 3 Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGF… Ended

2023-507964-38-00 Metastatic or Locally Advanced Epidermal Growth Factor 5 2022-09-01
Study of DS-1062a with or without Pembrolizumab in Advanced or Metastatic Non-small Cell Lung Cancer without Actionable Genomic Alterations Ended

2023-507933-12-00 Advanced or Metastatic Non-small Cell Lung Cancer (NSCL 5 2022-08-18
SEQUEL-Breast: a phase 2 study on the combination of alpelisib and fulvestrant after progression on previous therapy with fulvestrant in pat… Ended

2024-514965-20-00 Breast cancer 4 2022-06-02
A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended

2023-507795-51-00 atherosclerotic heart and blood vessel disease (the nar 5 2022-05-17